The Harvard contract comes as the prestigious university renews its focus on psychedelic research.
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC: MDXXF) will supply MDMA for a clinical trial at Harvard Medical School’s McLean Hospital, the company announced Wednesday.
McLean Hospital, located in Belmont, Massachusetts, is the largest psychiatric research facility affiliated with Harvard Medical School. Financial terms of the agreement were not disclosed.
PharmAla, which specializes in MDMA research and manufacturing, says it’s currently the only supplier of clinical-grade MDMA for patient treatments outside of clinical trials.
The company introduced an online tool to help researchers access its MDMA products and adapt their clinical trial protocols to its specifications.
PharmAla also announced plans to attend the CPHI pharmaceutical conference in Milan, where Shane Morris, the company’s chief operating officer, hinted that management would be meeting with potential European distribution partners.
“Over the past few months, PharmAla has been in discussion with a number of potential distribution partners in the European market,” Morris noted.
The Harvard contract comes as the university renews its focus on psychedelic research. In 2023, Harvard announced a $16 million program to study psychedelics in society and culture, marking a shift from its controversial psychedelic research history in the 1960s.
PharmAla stressed its focus on maintaining strong relationships with regulators, describing itself as a “regulatory first” organization.
[[{“value”:”The Harvard contract comes as the prestigious university renews its focus on psychedelic research.
The post PharmAla Biotech to supply MDMA for Harvard med school clinical trial appeared first on Green Market Report.”}]] Read More